Our Company
Our Mission & Commitment
Key Facts
Leadership
Governance
History
Compliance & Ethics
Diversity & Inclusion
Our Websites
Achievements
Business Information
R&D
R&D Strategy
In the Pipeline
Disease Areas of Focus
Our R&D
Our Science
R&D Highlights
Major R&D Facilities
Clinical Trials
Products
Patient Assistance Programs
Prescribing Information
R&D
Clinical Trials
Counterfeit Drugs
Product Information Inquiries
News
Press Releases
Publications
Media Library
Key Facts
Leadership
Financial Reporting
Features
Achievements
Media Contacts
Subscribe to e-mail alerts
Investors
Key Facts
Stock Information
SEC Filings
Financial Reporting
Events & Presentations
Shareholder Services
Investor Contacts
Partnering
Why Partner With Us?
Areas of Interest
Our Process
Our Partners
Partnering News
Partnering Contact
Responsibility
Bristol-Myers Squibb Foundation
Sustainability
Patient Assistance Programs
Building Our Communities
Grants & Giving
Position on Key Issues
Clinical Trials
Combating Counterfeit Drugs
Achievements
Careers
Job Opportunities
Our Culture
Diversity & Inclusion
Developing Our People
University Recruitment
Achievements
Benefits
Manage My Profile
Apply Now
SITE INDEX
|
CONTACT US
|
TERMS
|
PRIVACY
Health Care Professionals
Access
medical information and resources
Clinical Trials
Bristol-Myers Squibb-sponsored
clinical trials
Need Help Paying for Your Bristol-Myers Squibb Medicines?
Learn about our
assistance programs
.
Our Environmental Stewardship
Top 50 Company for Executive Women
The National Association for Female Executives
selects Bristol-Myers Squibb
for the eighth straight year.
LATEST NEWS
March 17, 2010
U.S. Food And Drug Administration Accepts New Drug Application For Once-Daily Fixed Dose Combination Of Onglyza™ (Saxagliptin) And Extended Release Metformin For The Treatment Of Type 2 Diabetes Mellitus In Adults
March 12, 2010
Sanofi-aventis and Bristol-Myers Squibb Announce Important Updates to PLAVIX U.S. Prescribing Information
March 9, 2010
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
March 8, 2010
Bristol-Myers Squibb to Present at Cowen and Company Health Care Conference